M&AHealthcareSIGNED
GSK Secures License for Chinese Cancer Drug for €637 Million
Value
€637M
Acquirer
GSK
Target
Chinese Cancer Drug License
British pharmaceutical giant GSK has obtained the licensing rights for a Chinese cancer drug in a deal valued at €637 million. This agreement is part of a series of international pacts by GSK, reflecting the growing influence of China's biotech sector.
The Meridian Weekly
The week's largest deals and the Iberian ones, every Monday. Free.